Rhythm Pharmaceuticals anuncia la autorización de la Comisión Europea de IMCIVREE® (setmelanotida)▼ para el tratamiento de la obesidad y el control del hambre asociados a la deficiencia de POMC, PCSK1 y LEPR

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing